This review is important because it turns cell-free DNA from a narrow laboratory marker into a larger strategy for understanding and managing rheumatoid arthritis.
As people age, damaged or dying cells release more DNA fragments into the body. These fragments are called cell-free DNA, or cfDNA. In small amounts, they may be harmless. But when they build up, especially in inflamed joints, they can act like false danger signals. The immune system may respond as if there is an infection, even though the signal comes from the body itself.
The novelty of this paper is its broad framework. It brings together evidence that cfDNA may help explain why aging increases RA risk, why inflammation continues, and why early detection is still difficult. The review also discusses how cfDNA could be measured in blood or synovial fluid to support diagnosis, disease monitoring, and risk prediction. It highlights molecular details such as cfDNA level, fragment size, methylation patterns, and tissue origin as possible clues to disease activity.
For the cluster topic of immune tolerance, this paper gives the roadmap. Immune tolerance fails when the body no longer knows how to ignore harmless self-signals. cfDNA may be
one of those self-signals. By understanding how cfDNA is produced, detected, and cleared, researchers may identify new ways to stop RA before inflammation becomes deeply established.
This paper therefore connects mechanism with clinical possibility: prevention, early diagnosis, and treatment may all begin with learning how the body handles its own DNA fragments.
References
N. Ma et al., “Targeting age-related cell-free DNA for prevention, early diagnosis and treatment of rheumatoid arthritis,” Autoimmunity Reviews, vol. 25, article 103961, 2026. Doi: 10.1016/j.autrev.2025.103961
